Chemomab Therapeutics (CMMB) Change in Account Payables (2018 - 2023)
Chemomab Therapeutics posted quarterly Change in Account Payables of -$215000.0 for Q4 2023, down 148.75% year-on-year from $441000.0 in Q4 2022, and up 86.7% on a QoQ basis from -$1.6 million in Q3 2023.
Chemomab Therapeutics (CMMB) has 6 years of Change in Account Payables data on file, last reported at -$215000.0 in Q4 2023.
- For the quarter ending Q4 2023, Change in Account Payables fell 148.75% year-over-year to -$215000.0; the trailing twelve-month figure through Dec 2023 stood at -$1.2 million (down 432.95% YoY), and the FY2025 full-year result was -$177000.0, down 251.28% from the prior year.
- Change in Account Payables for Q4 2023 stood at -$215000.0, up from -$1.6 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $854000.0 in Q4 2021 and bottomed at -$1.6 million in Q3 2023.
- The 5-year median for Change in Account Payables is $98000.0 (2020), against an average of $74950.0.
- The widest annual swing landed in 2021, when Change in Account Payables soared 1193.94%; it then tumbled 2166.67% in 2022.
- A 5-year view of Change in Account Payables shows it stood at $163000.0 in 2019, then sank by 59.51% to $66000.0 in 2020, then jumped by 1193.94% to $854000.0 in 2021, then plunged by 48.36% to $441000.0 in 2022, then tumbled by 148.75% to -$215000.0 in 2023.
- The last three Change in Account Payables figures came in at -$215000.0 (Q4 2023), -$1.6 million (Q3 2023), and $130000.0 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -215,000.00 |
| Dec 31, 2023 | -215,000.00 |
| Sep 30, 2023 | -1.62 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 31,000.00 |
| Mar 31, 2021 | 281,000.00 |
| Mar 31, 2021 | 281,000.00 |
| Dec 31, 2020 | 66,000.00 |
| Dec 31, 2020 | 66,000.00 |
| Sep 30, 2020 | -202,000.00 |
| Sep 30, 2020 | -202,000.00 |
| Jun 30, 2020 | 167,000.00 |
| Jun 30, 2020 | 167,000.00 |
| Mar 31, 2020 | 37,000.00 |
| Mar 31, 2020 | 37,000.00 |
| Dec 31, 2019 | 163,000.00 |
| Dec 31, 2019 | 163,000.00 |
| Sep 30, 2019 | 329,000.00 |
| Sep 30, 2019 | 329,000.00 |
| Jun 30, 2019 | -120,000.00 |
| Jun 30, 2019 | -120,000.00 |
| Mar 31, 2019 | 704,000.00 |
| Mar 31, 2019 | 704,000.00 |
| Dec 31, 2018 | -419,000.00 |
| Dec 31, 2018 | -419,000.00 |
| Sep 30, 2018 | -972,000.00 |
| Sep 30, 2018 | -972,000.00 |